Kidney Injury Molecule-1 and the Loss of Kidney Function in Diabetic Nephropathy: A Likely Causal Link in Patients With Type 1 Diabetes
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We evaluated the predictive value and clinical benefit of urinary kidney injury molecule (KIM)-1 for progression of diabetic nephropathy (DN) in type 1 diabetes. We also investigated its causal role for the decrease of estimated glomerular filtration rate (eGFR) by a Mendelian randomization (MR) approach. RESEARCH DESIGN AND METHODS: We followed 1,573 patients with type 1 diabetes for 6 years. KIM-1 was measured at baseline and normalized with urinary creatinine. KIM-1 predictive value was evaluated by Cox regression, while its added predictive benefit was evaluated using a panel of statistical indexes. The causality for the loss of renal function was evaluated with MR, utilizing the top signal from our genome-wide association study (GWAS) as the instrumental variable. RESULTS: KIM-1 was not an independent predictor of progression of DN when adjusted for albumin excretion rate (AER) and added no prognostic benefit to AER or eGFR. In multiple regressions, KIM-1 was associated with lower eGFR independently of diabetes duration (β = −4.066; P < 0.0001) but not of AER. In our GWAS, rs2036402 in the KIM1 gene was strongly associated with KIM-1 (β = −0.51; P = 6.5 × 10−38). In the MR, KIM-1 was associated with lower eGFR, independently of diabetes duration and AER (β = −5.044; P = 0.040), suggesting a causal relationship. CONCLUSIONS: KIM-1 did not predict progression to end-stage renal disease independently of AER and added no prognostic benefit to current biomarkers. Nevertheless, the MR showed that the inverse association of increased KIM-1 levels with lower eGFR is likely to represent a causal link.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 1×
“basic progression models together with AER and eGFR was assessed by calculating category-less net reclassification improvement and integrated discrimination improvement indexes (26,27).”
MethodInstrumental Variables Regression with Weak Instruments
Staiger, D., & Stock, J. (1994) · doi:10.3386/t0151 · Cited by 5,302 · cited 1×
“The strength of the association was tested with F statistics, and values $10 were considered sufficient to ensure the validity of the MR analysis (28).”
MethodMendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes
Li, Y., Willer, C. J., Ding, J., Scheet, P., & Abecasis, G. R. (2010) · Genetic Epidemiology · doi:10.1002/gepi.20533 · Cited by 1,843
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Self-citationUse of Mendelian randomisation to assess potential benefit of clinical intervention.
Burgess, S., Butterworth, A., Malarstig, A., & Thompson, S. G. (2012) · BMJ · doi:10.1136/bmj.e7325 · Cited by 292 · cited 2×
“and eGFR was explored using the MR approach that uses genetic variants associated with KIM-1 levels to infer causality (20,21).”
Method
Cited by
Mendelian Randomization as an Approach to Assess Causality Using Observational Data
Sekula, P., Del Greco M, F., Pattaro, C., & Köttgen, A. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016010098 · Cited by 2,351
Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease
Gilbert, R. E. (2017) · Diabetes · doi:10.2337/db16-0796 · Cited by 362
Mori, Y., Ajay, A. K., Chang, J.-H., Mou, S., Zhao, H., Kishi, S., Li, J., Brooks, C. R., Xiao, S., Woo, H.-M., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.004 · Cited by 293
Biomarkers of diabetic kidney disease
Colhoun, H. M., & Marcovecchio, M. L. (2018) · Diabetologia · doi:10.1007/s00125-018-4567-5 · Cited by 270
Insights into predicting diabetic nephropathy using urinary biomarkers
Khan, N. U., Lin, J., Liu, X., Li, H., Lu, W., Zhong, Z., Zhang, H., Waqas, M., & Shen, L. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140475 · Cited by 90
Metadata
- Authors
- Panduru, N. M., Sandholm, N., Forsblom, C., Saraheimo, M., Dahlström, E. H., Thorn, L. M., Gordin, D., Tolonen, N., Wadén, J., Harjutsalo, V., Bierhaus, A., Humpert, P. M., & Groop, P.-H.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-03-17
- Volume
- 38
- Issue
- 6
- Pages
- 1130-1137
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2141115950
- Cited by
- 85
- References
- 6
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.